Juan R. Bustillo, M.D.
Associate Professor of Psychiatry and Neurosciences
Director, Clozapine Clinic; Attending Psychiatrist, Spanish-Speaking Clinic, MHC
· M.D., Colegio Mayor de Nuestra Senora del Rosario, Bogota, Colombia, 1985
· Residency, University of Texas, Galveston, 1987-91
· Research Fellowship, Maryland Psychiatric Research Center, 1993-96
Areas of Specialization: Magnetic Resonance Spectroscopy of schizophrenia; cognitive basis of schizophrenic symptomatology; pharmacological treatment of schizophrenia
I am interested in the understanding and treatment of schizophrenic disorders. I spend my time at UNM doing clinical research in schizophrenia, teaching residents at the UNM Psychiatric Center, medical students and psychiatry fellows and treating outpatients with chronic mental illness. I interact with faculty from the Departments of Neuroscience and Psychology as well as scientists from the MIND Institute, an Albuquerque-based agency devoted to neuroimaging research. I particularly enjoy mentoring residents and fellows interested in psychiatric research.
e-mail: jbustillo@salud.unm.edu
Selected Publications:
Bustillo J, Barrow R, Paz R, Tang J, Seraji-Bozorgzad N, Moore G, Bolognani F, Lauriello J, Perrone-Bizzozero N, Matthew P Galloway M. Long term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels, Neuropsychopharmacology, 2006, 31:751-756.
Paz R, Andreasen N, Daoud S, Conley R, Roberts R, Bustillo J, Perrone-Bizzozero N. Increased expression of activity dependent-genes in cerebellar glutamatergic neurons of patients with schizophrenia. American J Psychiatry, 2006 in press.
Abbott C, Bustillo J. What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update, Current Opinion Psychiatry, 2006, 19:135-139.
Lauriello J, Bustillo J and Keith SJ. Schizophrenia: scope of the problem. In: Saddock B and Saddock V (eds): Comprehensive Textbook of Psychiatry, Lippincot, Williams and Wilkins, 2005
Edgar, J.C., Miller, G.A., Moses, S.N., Thoma, R.J., Huang, M.X., Hanlon,
F.M., Weisend, M.P., Sherwood, A, Bustillo, J., Adler, L.E., Canive, J.M.
Cross-modal generality of the gating deficit in schizophrenia, Psychophysiology, 2005; 42,
318-327.
Rowland L, Astur R, Jung RE, Bustillo J, Lauriello J, Yeo R Selective Cognitive Impairments Associated with NMDA Receptor Blockade in Humans, Neuropsychopharmacology, 2005; 30(3):633-9.
Rowland L, Bustillo J, Mullins P, Jung R, Lenroot R, Landgraf E, Barrow R, Yeo R, Lauriello J, Brooks W. The effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4.0T proton magnetic resonance spectroscopy study, Am J Psychiatry, 2005 162: 394-396.
Lauriello J, Bustillo J, Shingler K. The first interview of a patient with psychosis: symptoms, safety and stabilization. Focus, 2004; 11:7-12.
Bustillo J, C Wolff, A Myers-y-Gutierrez, T Dettmer, T Cooper, A Allan, J Lauriello, C F Valenzuela. Treatment of rats with antipsychotic drugs: lack of an effect on N acetyl-aspartate levels, Schizophrenia Research, 2004; 66:31-39.
Mullins, P, Rowland L, Bustillo J, Bedrick, E, Lauriello J, Brooks W. Reproducibility of H-MRS measurements in schizophrenic patients, Magnetic Resonance in Medicine, 2003; 50 (4) 704-707.
Lenroot R, Bustillo J, Lauriello J, Keith S. Integrated treatment of schizophrenia, Psychiatric Services, 2003; 54:1499-1507.
Thoma RJ, Hanlon FM, Moses SN, Edgar JC, Huang M, Weisend MP, Irwin J, Sherwood A, Paulson K, Bustillo J, Adler LE, Miller GA, Canive JM. Lateralization of auditory sensory gating and neuropsychological dysfunction in schizophrenia. Am J Psychiatry, 2003;160:1595-1605
Lenroot R, Bustillo J. The psychosocial treatment of schizophrenia, Directions in Psychiatry, 2003; 15:187-200
Bustillo J, Lauriello J, Parker K, Hammond R, Rowland L, Bogenshutz M, Keith S. Treatment of weight gain with fluoxetine in olanzapine treated schizophrenic outpatients, Neuropsychopharmacology, 2003; 28:527-529
M.X.Huang, J.C. Edgar, R.J.Thoma, F.M. Hanlon, S.N. Moses, R.R. Lee, K.M. Paulson, M.P. Weisend, J Bustillo, L.E. Adler, G.A. Miller, J.M. Canive. Predicting EEG responses using MEG sources in superior temporal gyrus reveals source anomaly in patients with schizophrenia. Clinical Neurophysiology, 2003; 114:835-850
Bustillo J, Lauriello J, Rowland L, Thomson L, Petropoulus H, Hammond R, Hart B, Brooks W. Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure, Schizophrenia Research, 2002; 58:313-321
Bustillo J, Rowland L, Lauriello J, Petropoulus H, Hammond R, Hart B, Brooks W. Elevated choline concentrations in the caudate nucleus in antipsychotic-naive schizophrenia, American Journal of Psychiatry, 2002;159: 130-133
Bustillo J, Lauriello J, Rowland L, Jung R, Petropoulus H, Hart B, Blanchard J, Keith S, Brooks W. Effects of chronic haloperidol and clozapine treatments on frontal and caudate brain neurochemistry in schizophrenia, Psychiatry Research Neuroimaging, 2001;107/3:135-149
Lauriello J, Bustillo J. Medication treatments for schizophrenia: translating research findings into better outcomes. Journal of Psychiatric Practice, 2001;7:254-260.
Rowland L, Bustillo J, Lauriello J. Proton magnetic resonance spectroscopy (H-MRS) studies of schizophrenia. Seminars in Clinical Neuropsychiatry, 2001;6:121-130.
Lauriello J, Bustillo J, Horan W, Keith SJ. The patient with first episode psychosis. Journal of Psychiatric Practice, 2001;7:123-132.
Bustillo J, Lauriello J, Horan W, Keith SJ. The psychosocial treatment of schizophrenia: an update. American Journal of Psychiatry, Am J Psychiatry 2001;158: 163-175.
Lauriello J, Bustillo J, Keith SJ. Commentary: can intensive psychosocial treatments make a difference in a time of atypical antipsychotics and managed care? Schizophrenia Bulletin, 2000, 26:141-144
Bustillo J, Keith SJ and Lauriello J. Psychosocial Treatment of Schizophrenia. In: Saddock B and Saddock V (eds): Comprehensive Textbook of Psychiatry, Lippincot, Williams and Wilkins, 2000
Bustillo J, Lauriello J, Keith SJ. Schizophrenia: Improving outcome. Harvard Review of Psychiatry, 1999, 6:229-240
Lauriello J, Bustillo J, Keith SJ. A critical review of research on psychosocial treatment of schizophrenia. Biological Psychiatry, 1999, 46:1409-1417
Blanchard JJ, Squires D, Henry T, Horan WP, Bogenschutz M, Lauriello J, Bustillo J. Examining an affect regulation model of substance abuse in schizophrenia. Journal of Nervous and Mental Disease, 1999, 187:72-79
Bustillo J, Thaker G, Buchanan RW, Moran M, Kirkpatrick B, Carpenter WT. Visual information processing impairments in deficit and nondeficit schizophrenia. American Journal of Psychiatry, 1997, 154:647-654
Bustillo J, Buchanan RW, Irish D, Breier A. Differential effect of clozapine on weight: a controlled study. American Journal of Psychiatry, 1996, 153(6):817-819
Kirkpatrick B, Amador X, Yale S, Bustillo J, Buchanan RW, Tohen M. The deficit syndrome in the DSM-IV field trial: II. Depressive episodes and persecutory beliefs. Schizophrenia Research, 1996, 20 (1-2):79-90
Bustillo J, Kirkpatrick B, Buchanan RW. Neuroleptic treatment and negative symptoms in deficit and nondeficit schizophrenia. Biological Psychiatry, 1995, 38:64-67.
Bustillo J, Buchanan RW, Carpenter WT. Prodromal symptoms vs. early warning signs and clinical action in schizophrenia. Schizophrenia Bulletin, 1995, 21(4):553-559.
Bustillo J, Buchanan RW. Neuroleptic-induced emesis: a new indication for clozapine? Biological Psychiatry, 1995; 38: 194-195.
Current Grants:
2004-2005. (Co P.I. : Juan Bustillo, MD). University of New Mexico School of Medicine, Department of Neuroscience, Mental Illness Neuroscience Discovery Institute, “NMDA receptor dysfunction in schizophrenia: from human postmortem to animal models”. P.I. : Nora Perrone-Bizzozero, Ph.D $200,000
2002-2004. (Co-Investigator) "Functional Imaging Research in Schizophrenia" University of New Mexico site for the FIRST BIRN, NIH. P.I : John Lauriello
2002-2007. (Co-investigator). VA Medical Center and University of New Mexico School of Medicine, NIH-RO1 “Cortical basis of schizophrenia sensory gating deficit”, PI: J. Canive. $1,250,000
2001-2005. (Principal investigator: Juan Bustillo, MD). University of New Mexico School of Medicine, Department of Psychiatry, Mental Illness Neuroscience Discovery Institute, “Longitudinal assessment of brain neurochemistry early in schizophrenia with high-field proton spectroscopy as a predictor of functional deterioration”. $585,899
2001-2004. (Principal investigator: Juan Bustillo, MD). University of New Mexico School of Medicine, Department of Psychiatry, Theodore & Vada Stanley Foundation Treatment Trials grant, “Lamotrigine treatment of persistent symptoms in schizophrenic outpatients with partial response to clozapine”. $210,000
Updated: 9/19/2006